Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
H1 influenza antigen · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 15 μg of the H1 influenza antigen | ACTIVE_COMPARATOR | - |
| 7.5 μg of the H1 influenza antigen | ACTIVE_COMPARATOR | - |
| Placebo (no antigen) | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| H1 influenza antigen | BIOLOGICAL | Either 7.5 μg or 15 μg of the H1 influenza antigen |
Inclusion Criteria: * Male or female aged 18 - 39 years inclusive * Provide written informed consent to participate * Healthy participants without acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality o As determined by medical history, physi...
H1 influenza antigen is an investigational vaccine being studied for the prevention of influenza. It is currently in Phase 1 clinical development and is being evaluated in healthy volunteers aged 18 years and older. The vaccine is designed to elicit an immune response against the H1 influenza virus.
H1 influenza antigen is being developed by Icon Plc, a company traded on the NASDAQ under the ticker symbol ICLR. The company is conducting clinical trials to evaluate the safety and immunogenicity of this investigational influenza vaccine.
H1 influenza antigen is in Phase 1 clinical development. It is an investigational vaccine and has not yet been approved by regulatory authorities. A Phase 1 trial has been completed to assess its safety and immune response in healthy volunteers.
H1 influenza antigen has been studied in one clinical trial, identified as NCT06125717, titled 'Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP'. This was a randomized, double-blind, placebo-controlled study conducted in Canada with 45 healthy adult participants. The trial has been completed.
H1 influenza antigen is being evaluated as a vaccine delivered by the MIMIX MAP system, as described in the Phase 1 clinical trial NCT06125717. The study assessed the vaccine's safety and immunogenicity when administered via this delivery method in healthy volunteers.